250 related articles for article (PubMed ID: 32238854)
1. Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.
Hideshima T; Ogiya D; Liu J; Harada T; Kurata K; Bae J; Massefski W; Anderson KC
Leukemia; 2021 Jan; 35(1):177-188. PubMed ID: 32238854
[TBL] [Abstract][Full Text] [Related]
2. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
3. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
[TBL] [Abstract][Full Text] [Related]
4. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs.
Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
[TBL] [Abstract][Full Text] [Related]
6. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
Hayashi T; Hideshima T; Akiyama M; Podar K; Yasui H; Raje N; Kumar S; Chauhan D; Treon SP; Richardson P; Anderson KC
Br J Haematol; 2005 Jan; 128(2):192-203. PubMed ID: 15638853
[TBL] [Abstract][Full Text] [Related]
8. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
9. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
Fionda C; Abruzzese MP; Zingoni A; Cecere F; Vulpis E; Peruzzi G; Soriani A; Molfetta R; Paolini R; Ricciardi MR; Petrucci MT; Santoni A; Cippitelli M
Oncotarget; 2015 Sep; 6(27):23609-30. PubMed ID: 26269456
[TBL] [Abstract][Full Text] [Related]
10. Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation.
Fionda C; Stabile H; Molfetta R; Kosta A; Peruzzi G; Ruggeri S; Zingoni A; Capuano C; Soriani A; Paolini R; Gismondi A; Cippitelli M; Santoni A
Eur J Immunol; 2021 Nov; 51(11):2607-2617. PubMed ID: 34392531
[TBL] [Abstract][Full Text] [Related]
11. Homo-PROTACs for the Chemical Knockdown of Cereblon.
Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
[TBL] [Abstract][Full Text] [Related]
12. Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs.
Beedie SL; Huang PA; Harris EM; Strope JD; Mahony C; Chau CH; Vargesson N; Figg WD
FASEB J; 2020 Sep; 34(9):11395-11404. PubMed ID: 32677118
[TBL] [Abstract][Full Text] [Related]
13. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
14. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma cells' capacity to decompose H
Sebastian S; Zhu YX; Braggio E; Shi CX; Panchabhai SC; Van Wier SA; Ahmann GJ; Chesi M; Bergsagel PL; Stewart AK; Fonseca R
Blood; 2017 Feb; 129(8):991-1007. PubMed ID: 28028022
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
17. USP15 antagonizes CRL4
Nguyen TV
Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
19. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
[TBL] [Abstract][Full Text] [Related]
20. The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.
Shen C; Nayak A; Neitzel LR; Adams AA; Silver-Isenstadt M; Sawyer LM; Benchabane H; Wang H; Bunnag N; Li B; Wynn DT; Yang F; Garcia-Contreras M; Williams CH; Dakshanamurthy S; Hong CC; Ayad NG; Capobianco AJ; Ahmed Y; Lee E; Robbins DJ
Nat Commun; 2021 Sep; 12(1):5263. PubMed ID: 34489457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]